X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (310) 310
index medicus (240) 240
oncology (238) 238
conventional doxorubicin (203) 203
female (198) 198
chemotherapy (148) 148
cancer (134) 134
middle aged (128) 128
aged (116) 116
adult (110) 110
doxorubicin - administration & dosage (99) 99
treatment outcome (94) 94
male (93) 93
breast cancer (89) 89
antineoplastic combined chemotherapy protocols - therapeutic use (88) 88
breast neoplasms - drug therapy (84) 84
anthracyclines (79) 79
multicenter trial (77) 77
encapsulated doxorubicin (69) 69
doxorubicin (68) 68
care and treatment (66) 66
reduced cardiotoxicity (65) 65
cardiotoxicity (64) 64
pharmacology & pharmacy (64) 64
animals (61) 61
hematology (59) 59
phase-iii trial (59) 59
liposomes (58) 58
conventional chemotherapy (53) 53
doxorubicin - adverse effects (53) 53
metastatic breast-cancer (52) 52
cyclophosphamide (51) 51
pegylated liposomal doxorubicin (49) 49
aged, 80 and over (48) 48
breast neoplasms - pathology (47) 47
therapy (47) 47
antineoplastic combined chemotherapy protocols - adverse effects (44) 44
doxorubicin - analogs & derivatives (44) 44
health aspects (44) 44
medicine & public health (44) 44
randomized-trial (44) 44
liposome-encapsulated doxorubicin (43) 43
prognosis (43) 43
antineoplastic agents - administration & dosage (42) 42
antineoplastic agents - therapeutic use (42) 42
neoplasms - drug therapy (42) 42
disease-free survival (41) 41
research (41) 41
metastasis (39) 39
hematology, oncology and palliative medicine (38) 38
hepatocellular carcinoma (38) 38
survival rate (38) 38
doxorubicin - therapeutic use (37) 37
drug delivery systems (37) 37
conventional transarterial chemoembolization (36) 36
efficacy (36) 36
retrospective studies (36) 36
1st-line treatment (35) 35
tumors (35) 35
antineoplastic agents - adverse effects (34) 34
cyclophosphamide - administration & dosage (33) 33
clinical trials (32) 32
neoplasm metastasis (32) 32
drug therapy (31) 31
polyethylene glycols - administration & dosage (31) 31
transplantation (31) 31
trastuzumab (31) 31
adolescent (30) 30
antibiotics, antineoplastic - administration & dosage (30) 30
drugs (30) 30
trial (30) 30
antibiotics, antineoplastic - adverse effects (29) 29
liposomal doxorubicin (29) 29
pharmacokinetics (29) 29
risk factors (29) 29
survival (29) 29
cancer therapies (28) 28
combined modality therapy (28) 28
adjuvant chemotherapy (27) 27
neoplasm staging (27) 27
phase-ii trial (27) 27
bone-marrow-transplantation (26) 26
congestive-heart-failure (26) 26
dose-response relationship, drug (26) 26
metastatic breast cancer (26) 26
survival analysis (26) 26
toxicity (26) 26
1st-line therapy (25) 25
analysis (25) 25
antineoplastic combined chemotherapy protocols - administration & dosage (25) 25
high-dose chemotherapy (25) 25
mice (25) 25
non-hodgkins-lymphoma (25) 25
paclitaxel (25) 25
anthracycline (24) 24
drug-delivery (24) 24
nanoparticles (24) 24
anthracyclines - adverse effects (23) 23
antibiotics, antineoplastic - therapeutic use (23) 23
liver cancer (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2006, Volume 106, Issue 4, pp. 848 - 858
BACKGROUND. Pegylated liposomal doxorubicin has pharmacologic and safety advantages over conventional doxorubicin. METHODS. For this noninteriority trial, 192... 
Dexamethasone | Neutropenic fever | Drug toxicity | Multiple myeloma | Liposomes | Drug resistance | Doxorubicin | Pegylated liposomal doxorubicin | Vincristine | Neoplasms | dexamethasone | 1ST-LINE TREATMENT | multiple myeloma | vincristine | ONCOLOGY-GROUP | liposomes | COMBINATION THERAPY | neutropenic fever | CONVENTIONAL DOXORUBICIN | TRANSPLANTATION | pegylated liposomal doxorubicin | THALIDOMIDE PLUS DEXAMETHASONE | KAPOSIS-SARCOMA | ONCOLOGY | drug toxicity | REDUCED-DOSE DEXAMETHASONE | VAD | doxorubicin | drug resistance | neoplasms | DVD-T | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Fever - chemically induced | Multiple Myeloma - drug therapy | Doxorubicin - analogs & derivatives | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Administration, Oral | Catheterization, Central Venous | Treatment Outcome | Polyethylene Glycols - administration & dosage | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Infusions, Intravenous | Doxorubicin - adverse effects | Pharmaceutical research | Drugs | Myelocytic leukemia | Reports | Nonlymphoid leukemia | Research | Drug therapy, Combination | Drug therapy | Health aspects
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2016, Volume 58, pp. 112 - 121
Journal Article
Breast, The, ISSN 0960-9776, 2009, Volume 18, Issue 4, pp. 218 - 224
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 2010, Volume 143, Issue 1, pp. 120 - 127
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 02/2011, Volume 96, Issue 2, pp. 245 - 252
Journal Article
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2018, Volume 82, Issue 3, pp. 521 - 532
Journal Article
Journal Article